ALDX · Company research
Aldeyra Therapeutics, Inc. (ALDX): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
35records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a Week | Ultragenyx Pharmaceutical agreed to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $203 million following FDA approval of Fayuvi, a gene therapy for mucopolysaccharidosis type IIIA. This marks the company's second PRV sale in one week, with the previous Genglycos voucher sale generating $210 million. Both transactions provide non-dilutive funding to support pipeline development and profitability goals. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 0.25 | 1 |
| RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a Week | Ultragenyx Pharmaceutical agreed to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $203 million following FDA approval of Fayuvi, a gene therapy for mucopolysaccharidosis type IIIA. This marks the company's second PRV sale in one week, with the previous Genglycos voucher sale generating $210 million. Both transactions provide non-dilutive funding to support pipeline development and profitability goals. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 0.25 | 1 |
| Here's Why You Should Add ANRO Stock to Your Portfolio Now | Alto Neuroscience (ANRO), a clinical-stage biopharmaceutical company, is advancing its precision psychiatry pipeline with three key candidates. ALTO-207 for treatment-resistant depression showed encouraging phase IIa results, with phase IIb results expected in H2 2027. ALTO-300 and ALTO-100 are in phase IIb studies with top-line results expected in H1 2027 and mid-2027 respectively. ALTO-101 for schizophrenia-related cognitive impairment failed its primary endpoint but showed some secondary signals. Year-to-date, ANRO shares have risen 24.1%, outperforming the biotech industry's 2.9% growth. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bullish | 0.25 | 1 |
| Here's Why You Should Add ANRO Stock to Your Portfolio Now | Alto Neuroscience (ANRO), a clinical-stage biopharmaceutical company, is advancing its precision psychiatry pipeline with three key candidates. ALTO-207 for treatment-resistant depression showed encouraging phase IIa results, with phase IIb results expected in H2 2027. ALTO-300 and ALTO-100 are in phase IIb studies with top-line results expected in H1 2027 and mid-2027 respectively. ALTO-101 for schizophrenia-related cognitive impairment failed its primary endpoint but showed some secondary signals. Year-to-date, ANRO shares have risen 24.1%, outperforming the biotech industry's 2.9% growth. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bullish | 0.25 | 1 |
| Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary Goal | Syndax Pharmaceuticals (SNDX) shares fell 15.7% after its phase II MAXPIRe study of axatilimab failed to meet the primary endpoint in idiopathic pulmonary fibrosis (IPF) treatment. The drug showed no benefit in slowing FVC decline, though it maintained a favorable safety profile. The company is discontinuing IPF development but will continue pursuing axatilimab in chronic graft-versus-host disease (cGVHD) with results expected in 2026 and 2028. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | neutral | 0 | 1 |
| Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary Goal | Syndax Pharmaceuticals (SNDX) shares fell 15.7% after its phase II MAXPIRe study of axatilimab failed to meet the primary endpoint in idiopathic pulmonary fibrosis (IPF) treatment. The drug showed no benefit in slowing FVC decline, though it maintained a favorable safety profile. The company is discontinuing IPF development but will continue pursuing axatilimab in chronic graft-versus-host disease (cGVHD) with results expected in 2026 and 2028. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | neutral | 0 | 1 |
| Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why | Prime Medicine (PRME) has achieved significant regulatory and clinical progress, receiving FDA clearance for PM647 targeting alpha-1 antitrypsin deficiency and dosing the first patient in a phase I/II trial of PM577a for Wilson disease. The stock has gained 26% over the past month, outperforming the biotech industry's 2.8% decline, driven by these encouraging developments in its Prime Editing platform for genetic disease treatments. | View source ↗ | Zacks Investment Research | Oct 12, 2026 | bullish | 0.4 | 1 |
| PMVP Stock Rises 19% in 3 Months: Here's What You Need to Know | PMV Pharmaceuticals (PMVP) has gained nearly 19% in three months following encouraging clinical data for its lead drug rezatapopt, which achieved a 46% response rate in ovarian cancer patients. The company plans to submit an NDA in Q1 2027 and raised $50.8 million through a public offering to fund operations into Q1 2028. | View source ↗ | Zacks Investment Research | Oct 12, 2026 | bullish | 0.4 | 1 |
| argenx Meets Primary Endpoint in Phase II Celiac Disease Study | argenx announced positive phase II results for FB102, an investigational therapy for celiac disease, meeting its primary endpoint with significant improvements in intestinal tissue measures versus placebo and no new safety signals. The company plans to advance FB102 into late-stage development and evaluate it for other autoimmune conditions. However, the stock declined nearly 12% following a separate announcement that argenx discontinued its phase III UNITY study for Vyvgart Hytrulo in Sjögren's disease. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | neutral | 0 | 1 |
| EDIT Set to Begin First-in-Human Study in Hypercholesterolemia | Editas Medicine announced approval to initiate the Strive phase I/II clinical study of EDIT-401, an investigational in vivo gene-editing therapy for heterozygous familial hypercholesterolemia (HeFH) in Australia. The single-dose therapy demonstrated approximately 90% or greater reductions in atherogenic lipoproteins in preclinical primate studies. Patient dosing is planned for 2026 with initial safety data expected in Q1 2027. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 0.25 | 1 |
| EDIT Set to Begin First-in-Human Study in Hypercholesterolemia | Editas Medicine announced approval to initiate the Strive phase I/II clinical study of EDIT-401, an investigational in vivo gene-editing therapy for heterozygous familial hypercholesterolemia (HeFH) in Australia. The single-dose therapy demonstrated approximately 90% or greater reductions in atherogenic lipoproteins in preclinical primate studies. Patient dosing is planned for 2026 with initial safety data expected in Q1 2027. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 0.25 | 1 |
| Here's Why You Should Add LPCN Stock to Your Portfolio Now | Lipocine (LPCN) is an emerging specialty pharmaceutical company with an approved oral testosterone replacement therapy (Tlando) generating royalties and expanding internationally. The company's key near-term catalyst is Brlizio (LPCN 1154), an oral brexanolone treatment for postpartum depression entering phase III BLOOM study in late 2026. LPCN carries a Zacks Rank #2 (Buy) with a broader pipeline targeting depression, obesity, epilepsy, and liver cirrhosis. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | neutral | 0 | 1 |
| Here's Why You Should Add LPCN Stock to Your Portfolio Now | Lipocine (LPCN) is an emerging specialty pharmaceutical company with an approved oral testosterone replacement therapy (Tlando) generating royalties and expanding internationally. The company's key near-term catalyst is Brlizio (LPCN 1154), an oral brexanolone treatment for postpartum depression entering phase III BLOOM study in late 2026. LPCN carries a Zacks Rank #2 (Buy) with a broader pipeline targeting depression, obesity, epilepsy, and liver cirrhosis. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | neutral | 0 | 1 |
| Here's Why You Should Add LPCN Stock to Your Portfolio Now | Lipocine (LPCN) is an emerging specialty pharmaceutical company with an approved oral testosterone replacement therapy (Tlando) generating royalties and expanding internationally. The company's key near-term catalyst is Brlizio (LPCN 1154), an oral brexanolone treatment for postpartum depression entering phase III BLOOM study in late 2026. LPCN carries a Zacks Rank #2 (Buy) with a broader pipeline targeting depression, obesity, epilepsy, and liver cirrhosis. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | neutral | 0 | 1 |
| Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash | Ultragenyx Pharmaceutical has entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $210 million following FDA approval of its gene therapy Genglycos. After a $42 million NIH payment obligation, approximately $168 million in non-dilutive capital will support the company's research, development, and commercialization efforts, helping it move toward profitability without equity financing. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.25 | 1 |
| Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash | Ultragenyx Pharmaceutical has entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $210 million following FDA approval of its gene therapy Genglycos. After a $42 million NIH payment obligation, approximately $168 million in non-dilutive capital will support the company's research, development, and commercialization efforts, helping it move toward profitability without equity financing. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.25 | 1 |
| Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash | Ultragenyx Pharmaceutical has entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $210 million following FDA approval of its gene therapy Genglycos. After a $42 million NIH payment obligation, approximately $168 million in non-dilutive capital will support the company's research, development, and commercialization efforts, helping it move toward profitability without equity financing. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.25 | 1 |
| Aldeyra Therapeutics, Inc. (ALDX) Stock Price, News, Quote & History - Yahoo! Finance Canada | Aldeyra Therapeutics, Inc. (ALDX) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 7, 2026 | neutral | 0 | 0.6 |
| ETON Stock Surges 108% in Six Months: Here's What You Need to Know | Eton Pharmaceuticals has gained 108% over six months, driven by 99% Q2 product sales growth and successful Hemangeol relaunch. The company raised 2026 revenue guidance to above $145 million with 35%+ adjusted EBITDA margins. Pipeline expansion including new launches and late-stage candidates like ASN-001 provide additional growth opportunities. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | bullish | 0.25 | 1 |
| PCRX Expands Exparel Commercial Reach in Europe Through Molteni Deal | Pacira BioSciences announced an exclusive agreement with Italian pharmaceutical company Molteni Farmaceutici to distribute and commercialize Exparel across the EU and UK. Molteni will launch the long-acting local anesthetic in Italy, Germany, Austria, and Poland starting in 2027, while Pacira retains manufacturing rights and will receive upfront payments, supply fees, and royalties. The deal supports Pacira's international expansion strategy while the company advances other pain management products including Zilretta and PCRX-201. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | bullish | 0.25 | 1 |
| PCRX Expands Exparel Commercial Reach in Europe Through Molteni Deal | Pacira BioSciences announced an exclusive agreement with Italian pharmaceutical company Molteni Farmaceutici to distribute and commercialize Exparel across the EU and UK. Molteni will launch the long-acting local anesthetic in Italy, Germany, Austria, and Poland starting in 2027, while Pacira retains manufacturing rights and will receive upfront payments, supply fees, and royalties. The deal supports Pacira's international expansion strategy while the company advances other pain management products including Zilretta and PCRX-201. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | bullish | 0.25 | 1 |
| Aldeyra Fights Back Against FDA Rejection, Dispute Plan Triggers Rally - TradingView | Aldeyra Fights Back Against FDA Rejection, Dispute Plan Triggers Rally TradingView | View source ↗ | TradingView | Sep 29, 2026 | neutral | 0 | 0.6 |
| After three FDA denial letters, Aldeyra plans a formal challenge over its dry eye drug. - Stock Titan | After three FDA denial letters, Aldeyra plans a formal challenge over its dry eye drug. Stock Titan | View source ↗ | Stock Titan | Sep 29, 2026 | neutral | 0 | 0.6 |
| $ALDX stock is down 12% today. Here's what we see in our data. - Quiver Quantitative | $ALDX stock is down 12% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Jul 16, 2026 | neutral | 0 | 0.6 |
| Aldeyra Therapeutics: What Comes Next After Reproxalap's Third CRL (NASDAQ:ALDX) - Seeking Alpha | Aldeyra Therapeutics: What Comes Next After Reproxalap's Third CRL (NASDAQ:ALDX) Seeking Alpha | View source ↗ | Seeking Alpha | Jul 10, 2026 | neutral | 0 | 0.6 |
| $ALDX stock is up 12% today. Here's what we see in our data. - Quiver Quantitative | $ALDX stock is up 12% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Jul 1, 2026 | neutral | 0 | 0.6 |
| ALDX Forecast — Price Target — Prediction for 2027 - TradingView | ALDX Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Jun 27, 2026 | neutral | 0 | 0.6 |
| ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Failed To Disclose Inconsistent Trial Data: Levi & Korsinsky - PR Newswire | ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Failed To Disclose Inconsistent Trial Data: Levi & Korsinsky PR Newswire | View source ↗ | PR Newswire | May 6, 2026 | neutral | 0 | 0.6 |
| ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Reiterated Misleading Claims: Levi & Korsinsky - PR Newswire | ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Reiterated Misleading Claims: Levi & Korsinsky PR Newswire | View source ↗ | PR Newswire | Apr 15, 2026 | neutral | 0 | 0.6 |
| $ALDX Lawsuit: Aldeyra Therapeutics, Inc. Sued for - GlobeNewswire | $ALDX Lawsuit: Aldeyra Therapeutics, Inc. Sued for GlobeNewswire | View source ↗ | GlobeNewswire | Mar 31, 2026 | neutral | 0 | 0.6 |
| ALDX Investor Alert: Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Overstated Drug Approval Prospects: Levi & Korsinsky - PR Newswire | ALDX Investor Alert: Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Overstated Drug Approval Prospects: Levi & Korsinsky PR Newswire | View source ↗ | PR Newswire | Mar 25, 2026 | neutral | 0 | 0.6 |
| Aldeyra Therapeutics (ALDX) Is Down 75.2% After FDA Rebuffs Dry Eye Drug Efficacy Data - Has The Bull Case Changed? - Simply Wall Street | Aldeyra Therapeutics (ALDX) Is Down 75.2% After FDA Rebuffs Dry Eye Drug Efficacy Data - Has The Bull Case Changed? Simply Wall Street | View source ↗ | Simply Wall Street | Mar 18, 2026 | neutral | 0 | 0.6 |
| Why Did ALDX Stock Tank 70% Today? - Stocktwits | Why Did ALDX Stock Tank 70% Today? Stocktwits | View source ↗ | Stocktwits | Mar 17, 2026 | neutral | 0 | 0.6 |
| Dry eye drug’s fast-acting promise stalls as FDA questions trial results - Stock Titan | Dry eye drug’s fast-acting promise stalls as FDA questions trial results Stock Titan | View source ↗ | Stock Titan | Mar 17, 2026 | neutral | 0 | 0.6 |
| Is Aldeyra Therapeutics (ALDX) Outperforming Other Medical Stocks This Year? - Yahoo Finance | Is Aldeyra Therapeutics (ALDX) Outperforming Other Medical Stocks This Year? Yahoo Finance | View source ↗ | Yahoo Finance | Feb 26, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.